CN110124048A - Multi-arm polyethylene glycol matrine conjugate, preparation method and application - Google Patents
Multi-arm polyethylene glycol matrine conjugate, preparation method and application Download PDFInfo
- Publication number
- CN110124048A CN110124048A CN201910325810.7A CN201910325810A CN110124048A CN 110124048 A CN110124048 A CN 110124048A CN 201910325810 A CN201910325810 A CN 201910325810A CN 110124048 A CN110124048 A CN 110124048A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- matrine
- arm polyethylene
- conjugate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/3311—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group
- C08G65/3312—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing a hydroxy group acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
Abstract
This application involves multi-arm polyethylene glycol matrine conjugate, preparation method and applications.The structure of the conjugate is as shown in the formula (I):
Description
Technical field
The present invention relates to field of pharmaceutical chemistry technology, more particularly to a kind of multi-arm polyethylene glycol matrine conjugate, its
Preparation method and application.
Background technique
Matrine is a kind of quinolizidine kind alkaloid, be mainly derived from leguminous plant Sophora alopecuroide, kuh-seng complete stool and
The rhizome of sophora tonkinensis Gapnep.Kuh-seng is recorded in Shennong's Herbal as medicinal plant earliest, is listed in top grade, continues to use two in China
More than thousand years, there is the effect of heat-clearing, diuresis, desinsection, clearing damp.Matrine is most important alkaloid in kuh-seng, has analgesia, resists
Inflammation, antibacterial, desinsection, antiviral and antitumor isoreactivity, and compound flavescent sophora root injection is made and applies and clinic.In matrine structure
Containing 5S, 6S, 7R, 4 carbon chiral centres of 11R and 2 chiral nitrogen centers have unique stereoeffect, and structure is such as
Under:
Matrine good water solubility dissolves in most of organic solvent.Recent study discovery, matrine have in vivo and in vitro
There is exact anti-tumor activity, plays antitumor action by a variety of mechanism of action, such as inhibit the proliferation of tumour cell, induction swollen
Apoptosis of tumor, inhibits tumor neovasculature formation, inhibits tumour the activity for promoting tumor cell differentiation, inhibiting Telomerase
It cell migration, reverse multiple drug resistance of tumor, modulate tumor cell autophagy and adjusts immune etc..But due to matrine water dissolubility
Greatly, it is very fast that process is eliminated in vivo, is generated that the active time is of short duration, is affected the performance of its drug effect.
Currently, people, which are concentrated mainly on the research of matrine, carries out structure of modification to matrine, to improve its physics and chemistry
Matter increases its action time in vivo, improves drug effect.For example, 13 substitutive derivatives of matrine, 14 of matrine take
For derivative, derivative and matrine lactam nucleus p-Coumaric acid etc. is transformed in 15- carbonyls.Although it is experimentally confirmed that part
The extended durations of action of matrine in vivo after structure of modification improves curative effect, but does not tie explicitly to its toxic side effect
By.
Polyethylene glycol (PEG) be U.S. FDA approval a few can be used for one of synthetic polymer of intravenously administrable, have
The advantages that having the dissolubility in water and many organic solvents, lacking toxicity and immune original shape.Due to the safety that it is proved,
Polyethylene glycol has been conjugated to activating agent, such as PEGylated interferon α -2a, PEGylated interferon α -2b and PEGylated granulocyte collection
G-CSF (PEG-GCSF) etc., the business success of said medicine, the active agent delivery ratio for also demonstrating conjugated form are not sewed
The relative medicine of conjunction has significant advantage.Small molecule such as Distearoyl Phosphatidylethanolamine, fluorouracil etc. is also PEGylated.
Although have these success, by PEG be connected on activating agent usually it is challenging and simultaneously not always successfully, for example, sewing
Closing attachable site is that necessary site, conjugation may cause active reduction later for pharmacological activity on activating agent
Even disappear.Therefore, it is thought that " reversible PEGylated ", i.e., PEGylated activating agent can degrade after entering in vivo, with release
Original activity agent or with increase active part activating agent.But this release often has randomness, can lead to undesirable
Degradation time is too long or too short.
Summary of the invention
Based on this, it is necessary to provide a kind of multi-arm polyethylene glycol matrine conjugate, which can after entering in vivo
Drug effect is played with desired degradation rate to discharge active matrine.
A kind of multi-arm polyethylene glycol matrine conjugate, shown in structure such as formula (I):
Wherein R is phenyl, and m is any integer between 2~6,
N is any integer between 24~240.
It should be noted thatTo be connected on phenyl on different carbon atoms
Arm, m are arm number.
By adjusting the numerical value of m, the drugloading rate of matrine can control.
Further, in order to avoid simple, the m preferably 2,4 or 6 of purification difficult and preparation, i.e. two arm polyethylene glycol kuh-sengs
Alkali conjugate, four arm polyethylene glycol matrine conjugates or six arm polyethylene glycol matrine conjugates,It is preferably attached on the carbon atom being centrosymmetric on phenyl, so that the conjugate
After reaching tumour cell environment, the matrine on dissimilar arm can be released simultaneously, to improve drug effect.
The structural formula of the multi-arm polyethylene glycol matrine conjugate is as follows in one of the embodiments:
N is any integer between 40~100 in one of the embodiments,.
Above-mentioned multi-arm polyethylene glycol matrine conjugate, including using phenyl as the multi-arm polyethylene glycol of center nuclear atom and
The matrine being connected by acylhydrazone key with multi-arm polyethylene glycol, the structure are stable under normal physiological context, and will not
Hydrolysis is to release matrine, and after reaching tumour cell environment, acylhydrazone key is degraded due to pH sensibility, is released
Matrine plays drug effect.Matrine is avoided since water solubility is big, tumour cell is not reached also and is just eliminated.And acylhydrazone key
It is degraded due to pH sensibility, release is former active matrine, and toxic side effect is clear.
In addition, above-mentioned multi-arm polyethylene glycol matrine conjugate avoids between arm and arm using phenyl as center nuclear atom
It crosslinks, then by the numerical value of control n, adjusts its lipid, swell so that the conjugate is reached with desired rate
Oncocyte environment, and be easy to be discharged after degradation.
The application also provides a kind of preparation method of multi-arm polyethylene glycol matrine conjugate, and concrete scheme is as follows:
A kind of preparation method of multi-arm polyethylene glycol matrine conjugate, includes the following steps S110~S130:
S110, multi-arm polyethylene glycol acetic acid and methanol are reacted, obtains multi-arm polyethylene glycol methyl acetate.
Wherein, the structural formula of multi-arm polyethylene glycol acetic acid is as follows:
Wherein R is phenyl, and m is any integer between 2~6, and n is any integer between 24~240.
It should be noted thatFor the arm being connected on phenyl on different carbon atoms, m is arm
Number.
Further, in order to avoid simple, the m preferably 2,4 or 6 of purification difficult and preparation, i.e. two arm polyethylene glycol acetic acid,
Four arm polyethylene glycol acetic acid or six arm polyethylene glycol acetic acid.
It is appreciated that the value of m is consistent with the numerical value of m needed for purpose product.The link position of arm also with purpose product arm
Link position it is consistent.
In the present embodiment, multi-arm polyethylene glycol acetic acid and the reaction temperature of methanol reaction are 60 DEG C~80 DEG C, reaction
Time is 12~24 hours.
The reaction equation of step S110 is as follows:
S120, by above-mentioned multi-arm polyethylene glycol methyl acetate and hydration hydrazine reaction, obtain multi-arm polyethylene glycol acethydrazide.
Wherein, the structural formula of multi-arm polyethylene glycol acethydrazide is as follows:
R, m and n are defined as above.
In the present embodiment, the reaction of multi-arm polyethylene glycol methyl acetate and hydrazine hydrate carries out in water, the temperature of reaction
Degree is 20 DEG C~35 DEG C, and the time of reaction is 12~24 hours.
The reaction equation of step S120 is as follows:
It should be noted that the methanol that step S120 is generated can recycle, to be recycled as the reaction raw materials of step S110,
Reduce production cost.
S130, above-mentioned multi-arm polyethylene glycol acethydrazide is reacted with matrine under the action of catalyst, obtains the poly- second of multi-arm
Glycol matrine conjugate.
Wherein, shown in the structure of multi-arm polyethylene glycol matrine conjugate such as formula (I):
M and n are defined as above.
In the present embodiment, catalyst is triethylamine.
In the present embodiment, the reaction temperature that multi-arm polyethylene glycol acethydrazide is reacted with matrine is 50 DEG C~70 DEG C,
Reaction time is 24~48 hours.
The reaction equation of step S130 is as follows:
The preparation method of above-mentioned multi-arm polyethylene glycol matrine conjugate is simple, and the methanol of generation can recycle,
Remaining only water generates, environmentally friendly, is suitble to scale industrial production.
The application also provides a kind of application of above-mentioned multi-arm polyethylene glycol matrine conjugate, and concrete scheme is as follows:
A kind of multi-arm polyethylene glycol matrine conjugate described in any of the above embodiments or multi-arm described in any of the above embodiments are poly-
Multi-arm polyethylene glycol matrine conjugate made from the preparation method of ethylene glycol matrine conjugate is in the preparation of antitumor drugs
Application.
The dosage form of the anti-tumor drug is injection, freeze-dried powder or implant in one of the embodiments,.
Specific embodiment
To facilitate the understanding of the present invention, below will to invention is more fully described, and give it is of the invention compared with
Good embodiment.But the invention can be realized in many different forms, however it is not limited to embodiment described herein.Phase
Instead, purpose of providing these embodiments is makes the disclosure of the present invention more thorough and comprehensive.
Unless otherwise defined, all technical and scientific terms used herein and belong to technical field of the invention
The normally understood meaning of technical staff is identical.Term as used herein in the specification of the present invention is intended merely to description tool
The purpose of the embodiment of body, it is not intended that in the limitation present invention.Term as used herein "and/or" includes one or more phases
Any and all combinations of the listed item of pass.
The preparation of 1 six arm polyethylene glycol matrine conjugate (6Arm-PEG10000- matrine) of embodiment
The preparation of (1) six arm polyethylene glycol methyl acetate (6Arm-PEG10000-MAA):
By the six arm polyethylene glycol acetic acid (6Arm-PEG10000-AC) of 1mmol, it is dissolved in 100ml anhydrous methanol, adds
Heat is reacted 12 hours to 60 DEG C.It is filtered to remove the solid that reaction generates, filtrate is concentrated to dryness, and residue is dissolved with methylene chloride,
Washing, organic phase are concentrated to dryness after drying, and crude product obtains 6Arm-PEG10000-MAA after passing through recrystallization purifying.Yield
92.2%.
The preparation of (2) six arm polyethylene glycol acethydrazides (6Arm-PEG10000-HZ)
0.5mmol 6Arm-PEG10000-MAA is dissolved in 150ml distilled water, the hydration of 50ml80% specification is added
Hydrazine, 25 DEG C are reacted for stirring 16 hours.TLC monitors fully reacting.The dissolution of 300ml methylene chloride, water is added in decompression concentrated solution
It washes, organic phase is further concentrated to dry, is repeated several times, and removes most hydrazine hydrates, and crude product methyl tertiary butyl ether(MTBE) precipitates crystallization, mistake
Precipitating is collected in filter, and 6Arm-PEG10000-HZ is made in vacuum drying.
The preparation of (3) six arm polyethylene glycol matrine conjugates (6Arm-PEG10000- matrine)
6Arm-PEG10000-HZ is dissolved in 200mlN, in dinethylformamide (DMF), 10 are added under nitrogen protection
The matrine of molar equivalent, finishes, and the triethylamine of 1mol equivalent is added, and reaction carries out 24 hours at a temperature of 60 DEG C.It crosses and filters out
Solid matter is removed, excess of solvent rotary evaporation removes, and residue adds 400ml methyl tertiary butyl ether(MTBE) recrystallization, filtering, product
It is vacuum dried, obtain six arm polyethylene glycol matrine conjugates.
The preparation of 2 six arm polyethylene glycol matrine conjugate (6Arm-PEG20000- matrine) of embodiment
The preparation of (1) six arm polyethylene glycol methyl acetate (6Arm-PEG20000-MAA):
By the six arm polyethylene glycol acetic acid (6Arm-PEG20000-AC) of 1mmol, 100ml is dissolved in without in methanol, is heated
To 80 DEG C, react 16 hours.It is filtered to remove the solid that reaction generates, filtrate is concentrated to dryness, and residue is dissolved with methylene chloride, water
It washes, organic phase is concentrated to dryness after drying, and crude product obtains 6Arm-PEG20000-MAA after passing through recrystallization purifying.Yield 91.8%
The preparation of (2) six arm polyethylene glycol acethydrazides (6Arm-PEG20000-HZ)
0.5mmol 6Arm-PEG20000-MAA is dissolved in 150ml distilled water, the hydration of 50ml80% specification is added
Hydrazine, 20 DEG C are reacted for stirring 24 hours.TLC monitors fully reacting.The dissolution of 300ml methylene chloride, water is added in decompression concentrated solution
It washes, organic phase is further concentrated to dry, is repeated several times, and removes most hydrazine hydrates, and crude product methyl tertiary butyl ether(MTBE) precipitates crystallization, mistake
Precipitating is collected in filter, and 6Arm-PEG20000-HZ is made in vacuum drying.
The preparation of (3) six arm polyethylene glycol matrine conjugates (6Arm-PEG20000- matrine)
6Arm-PEG20000-HZ is dissolved in 200mlDMF, and the matrine of 10 molar equivalents is added under nitrogen protection, adds
Finish, the triethylamine of 1mol equivalent is added, reaction carries out 28 hours at 50 °C.It is filtered to remove solid matter, excess of solvent
Rotary evaporation removes, and residue adds 400ml methyl tertiary butyl ether(MTBE) recrystallization, and filtering, product is vacuum dried, and it is poly- to obtain six arms
Ethylene glycol matrine conjugate.
The preparation of 3 six arm polyethylene glycol matrine conjugate (6Arm-PEG40000- matrine) of embodiment
The preparation of (1) six arm polyethylene glycol methyl acetate (6Arm-PEG40000-MAA):
By the six arm polyethylene glycol acetic acid (6Arm-PEG40000-AC) of 1mmol, 100ml is dissolved in without in methanol, is heated
To 70 DEG C, react 24 hours.It is filtered to remove the solid that reaction generates, filtrate is concentrated to dryness, and residue is dissolved with methylene chloride, water
It washes, organic phase is concentrated to dryness after drying, and crude product obtains 6Arm-PEG40000-MAA after passing through recrystallization purifying.Yield 93.4%
The preparation of (2) six arm polyethylene glycol acethydrazides (6Arm-PEG40000-HZ)
0.5mmol 6Arm-PEG40000-MAA is dissolved in 150ml distilled water, the hydration of 50ml80% specification is added
Hydrazine, 35 DEG C are reacted for stirring 12 hours.TLC monitors fully reacting.The dissolution of 300ml methylene chloride, water is added in decompression concentrated solution
It washes, organic phase is further concentrated to dry, is repeated several times, and removes most hydrazine hydrates, and crude product methyl tertiary butyl ether(MTBE) precipitates crystallization, mistake
Precipitating is collected in filter, and 6Arm-PEG40000-HZ is made in vacuum drying.
The preparation of (3) six arm polyethylene glycol matrine conjugates (6Arm-PEG40000- matrine)
6Arm-PEG40000-HZ is dissolved in 200mlDMF, and the matrine of 10 molar equivalents is added under nitrogen protection, adds
Finish, the triethylamine of 1mol equivalent is added, reaction carries out 48 hours at a temperature of 70 DEG C.It is filtered to remove solid matter, excess of solvent
Rotary evaporation removes, and residue adds 400ml methyl tertiary butyl ether(MTBE) recrystallization, and filtering, product is vacuum dried, and it is poly- to obtain six arms
Ethylene glycol-matrine.
The preparation of 4 two arm polyethylene glycol matrine conjugate (2Arm-PEG10000- matrine) of embodiment
The preparation of (1) two arm polyethylene glycol methyl acetate (2Arm-PEG10000-MAA):
By the two arm polyethylene glycol acetic acid (2Arm-PEG10000-AC) of 1mmol, it is dissolved in 100ml anhydrous methanol, adds
Heat is reacted 12 hours to 60 DEG C.It is filtered to remove the solid that reaction generates, filtrate is concentrated to dryness, and residue is dissolved with methylene chloride,
Washing, organic phase are concentrated to dryness after drying, and crude product obtains 2Arm-PEG10000-MAA after passing through recrystallization purifying.Yield
95.4%.
The preparation of (2) two arm polyethylene glycol acethydrazides (2Arm-PEG10000-HZ)
0.5mmol 2Arm-PEG10000-MAA is dissolved in 150ml distilled water, the hydration of 50ml80% specification is added
Hydrazine, 25 DEG C are reacted for stirring 16 hours.TLC monitors fully reacting.The dissolution of 300ml methylene chloride, water is added in decompression concentrated solution
It washes, organic phase is further concentrated to dry, is repeated several times, and removes most hydrazine hydrates, and crude product methyl tertiary butyl ether(MTBE) precipitates crystallization, mistake
Precipitating is collected in filter, and 2Arm-PEG10000-HZ is made in vacuum drying.
The preparation of (3) two arm polyethylene glycol matrine conjugates (2Arm-PEG10000- matrine)
2Arm-PEG10000-HZ is dissolved in 200mlN, in dinethylformamide (DMF), 10 are added under nitrogen protection
The matrine of molar equivalent, finishes, and the triethylamine of 1mol equivalent is added, and reaction carries out 24 hours at a temperature of 60 DEG C.It crosses and filters out
Solid matter is removed, excess of solvent rotary evaporation removes, and residue adds 400ml methyl tertiary butyl ether(MTBE) recrystallization, filtering, product
It is vacuum dried, obtain two arm polyethylene glycol matrine conjugates.
The preparation of 5 two arm polyethylene glycol matrine conjugate (2Arm-PEG20000- matrine) of embodiment
The preparation of (1) two arm polyethylene glycol methyl acetate (2Arm-PEG20000-MAA):
By the two arm polyethylene glycol acetic acid (2Arm-PEG20000-AC) of 1mmol, 100ml is dissolved in without in methanol, is heated
To 80 DEG C, react 16 hours.It is filtered to remove the solid that reaction generates, filtrate is concentrated to dryness, and residue is dissolved with methylene chloride, water
It washes, organic phase is concentrated to dryness after drying, and crude product obtains 2Arm-PEG20000-MAA after passing through recrystallization purifying.Yield 91.8%
The preparation of (2) two arm polyethylene glycol acethydrazides (2Arm-PEG20000-HZ)
0.5mmol 2Arm-PEG20000-MAA is dissolved in 150ml distilled water, the hydration of 50ml80% specification is added
Hydrazine, 20 DEG C are reacted for stirring 24 hours.TLC monitors fully reacting.The dissolution of 300ml methylene chloride, water is added in decompression concentrated solution
It washes, organic phase is further concentrated to dry, is repeated several times, and removes most hydrazine hydrates, and crude product methyl tertiary butyl ether(MTBE) precipitates crystallization, mistake
Precipitating is collected in filter, and 2Arm-PEG20000-HZ is made in vacuum drying.
The preparation of (3) two arm polyethylene glycol matrine conjugates (2Arm-PEG20000- matrine)
2Arm-PEG20000-HZ is dissolved in 200mlDMF, and the matrine of 10 molar equivalents is added under nitrogen protection, adds
Finish, the triethylamine of 1mol equivalent is added, reaction carries out 28 hours at 50 °C.It is filtered to remove solid matter, excess of solvent
Rotary evaporation removes, and residue adds 400ml methyl tertiary butyl ether(MTBE) recrystallization, and filtering, product is vacuum dried, and it is poly- to obtain two arms
Ethylene glycol matrine conjugate.
The preparation of 6 two arm polyethylene glycol matrine conjugate (2Arm-PEG40000- matrine) of embodiment
The preparation of (1) two arm polyethylene glycol methyl acetate (2Arm-PEG40000-MAA):
By the two arm polyethylene glycol acetic acid (2Arm-PEG40000-AC) of 1mmol, 100ml is dissolved in without in methanol, is heated
To 70 DEG C, react 24 hours.It is filtered to remove the solid that reaction generates, filtrate is concentrated to dryness, and residue is dissolved with methylene chloride, water
It washes, organic phase is concentrated to dryness after drying, and crude product obtains 2Arm-PEG40000-MAA after passing through recrystallization purifying.Yield 93.4%
The preparation of (2) two arm polyethylene glycol acethydrazides (2Arm-PEG40000-HZ)
0.5mmol 2Arm-PEG40000-MAA is dissolved in 150ml distilled water, the hydration of 50ml80% specification is added
Hydrazine, 35 DEG C are reacted for stirring 12 hours.TLC monitors fully reacting.The dissolution of 300ml methylene chloride, water is added in decompression concentrated solution
It washes, organic phase is further concentrated to dry, is repeated several times, and removes most hydrazine hydrates, and crude product methyl tertiary butyl ether(MTBE) precipitates crystallization, mistake
Precipitating is collected in filter, and 2Arm-PEG40000-HZ is made in vacuum drying.
The preparation of (3) two arm polyethylene glycol matrine conjugates (2Arm-PEG40000- matrine)
2Arm-PEG40000-HZ is dissolved in 200mlDMF, and the matrine of 10 molar equivalents is added under nitrogen protection, adds
Finish, the triethylamine of 1mol equivalent is added, reaction carries out 48 hours at a temperature of 70 DEG C.It is filtered to remove solid matter, excess of solvent
Rotary evaporation removes, and residue adds 400ml methyl tertiary butyl ether(MTBE) recrystallization, and filtering, product is vacuum dried, and it is poly- to obtain two arms
Ethylene glycol-matrine.
The preparation of 7 four arm polyethylene glycol matrine conjugate (4Arm-PEG10000- matrine) of embodiment
The preparation of (1) four arm polyethylene glycol methyl acetate (4Arm-PEG10000-MAA):
By the four arm polyethylene glycol acetic acid (4Arm-PEG10000-AC) of 1mmol, it is dissolved in 100ml anhydrous methanol, adds
Heat is reacted 12 hours to 60 DEG C.It is filtered to remove the solid that reaction generates, filtrate is concentrated to dryness, and residue is dissolved with methylene chloride,
Washing, organic phase are concentrated to dryness after drying, and crude product obtains 4Arm-PEG10000-MAA after passing through recrystallization purifying.Yield
92.2%.
The preparation of (2) four arm polyethylene glycol acethydrazides (4Arm-PEG10000-HZ)
0.5mmol 4Arm-PEG10000-MAA is dissolved in 150ml distilled water, the hydration of 50ml80% specification is added
Hydrazine, 25 DEG C are reacted for stirring 16 hours.TLC monitors fully reacting.The dissolution of 300ml methylene chloride, water is added in decompression concentrated solution
It washes, organic phase is further concentrated to dry, is repeated several times, and removes most hydrazine hydrates, and crude product methyl tertiary butyl ether(MTBE) precipitates crystallization, mistake
Precipitating is collected in filter, and 4Arm-PEG10000-HZ is made in vacuum drying.
The preparation of (3) four arm polyethylene glycol matrine conjugates (4Arm-PEG10000- matrine)
4Arm-PEG10000-HZ is dissolved in 200mlN, in dinethylformamide (DMF), 10 are added under nitrogen protection
The matrine of molar equivalent, finishes, and the triethylamine of 1mol equivalent is added, and reaction carries out 24 hours at a temperature of 60 DEG C.It crosses and filters out
Solid matter is removed, excess of solvent rotary evaporation removes, and residue adds 400ml methyl tertiary butyl ether(MTBE) recrystallization, filtering, product
It is vacuum dried, obtain four arm polyethylene glycol matrine conjugates.
The preparation of 8 four arm polyethylene glycol matrine conjugate (4Arm-PEG20000- matrine) of embodiment
The preparation of (1) four arm polyethylene glycol methyl acetate (4Arm-PEG20000-MAA):
By the four arm polyethylene glycol acetic acid (4Arm-PEG20000-AC) of 1mmol, 100ml is dissolved in without in methanol, is heated
To 80 DEG C, react 16 hours.It is filtered to remove the solid that reaction generates, filtrate is concentrated to dryness, and residue is dissolved with methylene chloride, water
It washes, organic phase is concentrated to dryness after drying, and crude product obtains 4Arm-PEG20000-MAA after passing through recrystallization purifying.Yield 91.8%
The preparation of (2) four arm polyethylene glycol acethydrazides (4Arm-PEG20000-HZ)
0.5mmol 4Arm-PEG20000-MAA is dissolved in 150ml distilled water, the hydration of 50ml80% specification is added
Hydrazine, 20 DEG C are reacted for stirring 24 hours.TLC monitors fully reacting.The dissolution of 300ml methylene chloride, water is added in decompression concentrated solution
It washes, organic phase is further concentrated to dry, is repeated several times, and removes most hydrazine hydrates, and crude product methyl tertiary butyl ether(MTBE) precipitates crystallization, mistake
Precipitating is collected in filter, and 4Arm-PEG20000-HZ is made in vacuum drying.
The preparation of (3) four arm polyethylene glycol matrine conjugates (4Arm-PEG20000- matrine)
4Arm-PEG20000-HZ is dissolved in 200mlDMF, and the matrine of 10 molar equivalents is added under nitrogen protection, adds
Finish, the triethylamine of 1mol equivalent is added, reaction carries out 28 hours at 50 °C.It is filtered to remove solid matter, excess of solvent
Rotary evaporation removes, and residue adds 400ml methyl tertiary butyl ether(MTBE) recrystallization, and filtering, product is vacuum dried, and it is poly- to obtain four arms
Ethylene glycol matrine conjugate.
The preparation of 9 four arm polyethylene glycol matrine conjugate (4Arm-PEG40000- matrine) of embodiment
The preparation of (1) four arm polyethylene glycol methyl acetate (4Arm-PEG40000-MAA):
By the four arm polyethylene glycol acetic acid (4Arm-PEG40000-AC) of 1mmol, 100ml is dissolved in without in methanol, is heated
To 70 DEG C, react 24 hours.It is filtered to remove the solid that reaction generates, filtrate is concentrated to dryness, and residue is dissolved with methylene chloride, water
It washes, organic phase is concentrated to dryness after drying, and crude product obtains 4Arm-PEG40000-MAA after passing through recrystallization purifying.Yield 93.4%
The preparation of (2) four arm polyethylene glycol acethydrazides (4Arm-PEG40000-HZ)
0.5mmol 4Arm-PEG40000-MAA is dissolved in 150ml distilled water, the hydration of 50ml80% specification is added
Hydrazine, 35 DEG C are reacted for stirring 12 hours.TLC monitors fully reacting.The dissolution of 300ml methylene chloride, water is added in decompression concentrated solution
It washes, organic phase is further concentrated to dry, is repeated several times, and removes most hydrazine hydrates, and crude product methyl tertiary butyl ether(MTBE) precipitates crystallization, mistake
Precipitating is collected in filter, and 4Arm-PEG40000-HZ is made in vacuum drying.
The preparation of (3) four arm polyethylene glycol matrine conjugates (4Arm-PEG40000- matrine)
4Arm-PEG40000-HZ is dissolved in 200mlDMF, and the matrine of 10 molar equivalents is added under nitrogen protection, adds
Finish, the triethylamine of 1mol equivalent is added, reaction carries out 48 hours at a temperature of 70 DEG C.It is filtered to remove solid matter, excess of solvent
Rotary evaporation removes, and residue adds 400ml methyl tertiary butyl ether(MTBE) recrystallization, and filtering, product is vacuum dried, and it is poly- to obtain four arms
Ethylene glycol-matrine.
It is inoculated in 96 orifice plates using human liver cancer cell 7402 and rectum cancer cell RKO as model cell, every 100 μ L of hole
(5000 cells), if blank group, control group and administration group (50 μM and 5 μM), every group sets 4 parallel holes.Set 37 DEG C, 5%
(V/V)CO2Incubator in, the drug of various concentration is added afterwards for 24 hours, continues to cultivate 48h, removes supernatant before terminating, it is every empty plus
Enter 30 μ L5mg/mLMTT, incubator removes MTT after being incubated for 4h and 100 holes μ LDMSO/ are added, and sets low-speed oscillation on shaking table
10min dissolves crystal sufficiently, measures each hole absorbance (OD) value at 570nm wavelength with microplate reader, and calculate cell
Survival rate.Experiment is repeated twice.
The calculation formula of cell survival rate: cell survival rate (%)=medicine group mean OD value/control group mean OD value ×
100%.
Experimental result is as shown in table 1.
Table 1
As can be seen from Table 1, in liver cancer cells 7402 and colon cancer RKO, when 50 μM of dosage, Examples 1 to 9 preparation
The activity intensity of multi-arm polyethylene glycol matrine conjugate is substantially better than the poly- second of six arms prepared by matrine, especially embodiment 2
Glycol matrine conjugate, activity intensity are best.In liver cancer cells 7402, when 5 μM of dosage, Examples 1 to 9 preparation
The activity intensity of multi-arm polyethylene glycol matrine conjugate is also significantly better than matrine.
The multi-arm polyethylene glycol matrine conjugate of Examples 1 to 9 preparation is subjected to stability test:
The multi-arm polyethylene glycol matrine conjugate difference of Examples 1 to 9 preparation is soluble in water, and being configured to concentration is phase
When being added in the aqueous solution of matrine 5mg/ml, mannitol is appropriate, and with the filtering of 0.20 micron membrane filter, filtrate is sub-packed in the XiLin 10ml
In bottle (5ml/ branch), freeze-drying, gland.Sample after freeze-drying is placed 5 days under illumination, hot conditions respectively, acceleration environment
(temperature 38, humidity 80%) places January, referring to the detection method of matrine raw material, is detected using high performance liquid chromatograph, equal nothing
Free matrine shows that the multi-arm polyethylene glycol matrine conjugate of the application has good stability.
Six arm polyethylene glycol matrine conjugates of Examples 1 to 9 preparation are subjected to extracorporeal hydrolysis test:
The accurate multi-arm polyethylene glycol matrine conjugate for weighing Examples 1 to 9 preparation is appropriate respectively, and every ml is made with water
Containing about the solution of matrine 0.2mg, with HCl solution tune pH value 6-7, be uniformly mixed, room temperature respectively at 0h, 0.5h, 1h, 1.5h,
Take solution appropriate when 4h, 8h, 12h, HPLC method detects the concentration (external standard method) of free third phenol.The result shows that the multi-arm of the application
Polyethylene glycol matrine conjugate can be decomposed into active matter matrine in weakly acidic condition water.
The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously
Limitations on the scope of the patent of the present invention therefore cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to guarantor of the invention
Protect range.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.
Claims (10)
1. a kind of multi-arm polyethylene glycol matrine conjugate, which is characterized in that shown in structure such as formula (I):
Wherein, R is phenyl, and m is any integer between 2~6, and n is any integer between 24~240.
2. multi-arm polyethylene glycol matrine conjugate according to claim 1, which is characterized in that the multi-arm polyethylene glycol
The structural formula of matrine conjugate is as follows:
。
3. multi-arm polyethylene glycol matrine conjugate according to claim 1 or 2, which is characterized in that n be 40~100 it
Between any integer.
4. a kind of preparation method of multi-arm polyethylene glycol matrine conjugate, which comprises the following steps:
Multi-arm polyethylene glycol acetic acid and methanol are reacted, multi-arm polyethylene glycol methyl acetate, the multi-arm polyethylene glycol second are obtained
The structural formula of acid is as follows:
The structural formula of the multi-arm polyethylene glycol methyl acetate is as follows:
By the multi-arm polyethylene glycol methyl acetate and hydration hydrazine reaction, multi-arm polyethylene glycol acethydrazide is obtained, the multi-arm is poly-
The structural formula of ethylene glycol ethyl ethers hydrazides is as follows:
The multi-arm polyethylene glycol acethydrazide is reacted with matrine under the action of catalyst, obtains multi-arm polyethylene glycol matrine
Conjugate, shown in the structure such as formula (I) of the multi-arm polyethylene glycol matrine conjugate:
The R is phenyl, and m is any integer between 2~6, and n is any integer between 24~240.
5. the preparation method of multi-arm polyethylene glycol matrine conjugate according to claim 4, which is characterized in that described to urge
Agent is triethylamine.
6. the preparation method of multi-arm polyethylene glycol matrine conjugate according to claim 4 or 5, which is characterized in that institute
The reaction temperature for stating multi-arm polyethylene glycol acetic acid and methanol reaction is 60 DEG C~80 DEG C, and the reaction time is 12~24 hours.
7. the preparation method of multi-arm polyethylene glycol matrine conjugate according to claim 4 or 5, which is characterized in that institute
The reaction for stating multi-arm polyethylene glycol methyl acetate and hydrazine hydrate carries out in water, and the temperature of reaction is 20 DEG C~35 DEG C, reaction
Time is 12~24 hours.
8. the preparation method of multi-arm polyethylene glycol matrine conjugate according to claim 4 or 5, which is characterized in that institute
Stating the reaction temperature that multi-arm polyethylene glycol acethydrazide is reacted with matrine is 50 DEG C~70 DEG C, and the reaction time is 24~48 hours.
9. a kind of described in any item multi-arm polyethylene glycol matrine conjugates of claims 1 to 3 or claim 4~8 are any
Multi-arm polyethylene glycol matrine conjugate made from the preparation method of multi-arm polyethylene glycol matrine conjugate described in is being made
Application in standby anti-tumor drug.
10. application according to claim 9, which is characterized in that the dosage form of the anti-tumor drug is injection, freeze-dried powder
Agent or implant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910325810.7A CN110124048B (en) | 2019-04-23 | 2019-04-23 | Multi-arm polyethylene glycol matrine conjugate, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910325810.7A CN110124048B (en) | 2019-04-23 | 2019-04-23 | Multi-arm polyethylene glycol matrine conjugate, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110124048A true CN110124048A (en) | 2019-08-16 |
| CN110124048B CN110124048B (en) | 2022-06-17 |
Family
ID=67570573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910325810.7A Active CN110124048B (en) | 2019-04-23 | 2019-04-23 | Multi-arm polyethylene glycol matrine conjugate, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110124048B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102475891A (en) * | 2010-11-23 | 2012-05-30 | 中国科学院化学研究所 | PH-responsive polyethylene glycol-anticarcinogen conjugate, and synthetic method and application thereof |
| CN103113466A (en) * | 2013-03-01 | 2013-05-22 | 中国科学院过程工程研究所 | Recombinant human interferon beta-1b modified by polyethylene glycol and preparation method of recombinant human interferon beta-1b |
| CN107137715A (en) * | 2017-04-26 | 2017-09-08 | 石家庄蒎格医药科技有限公司 | Prodrug and preparation is conjugated in a kind of 9-hydroxy-risperidone polyethylene glycol |
| CN108727582A (en) * | 2017-04-21 | 2018-11-02 | 博瑞生物医药（苏州）股份有限公司 | Target anticancer conjugate |
-
2019
- 2019-04-23 CN CN201910325810.7A patent/CN110124048B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102475891A (en) * | 2010-11-23 | 2012-05-30 | 中国科学院化学研究所 | PH-responsive polyethylene glycol-anticarcinogen conjugate, and synthetic method and application thereof |
| CN103113466A (en) * | 2013-03-01 | 2013-05-22 | 中国科学院过程工程研究所 | Recombinant human interferon beta-1b modified by polyethylene glycol and preparation method of recombinant human interferon beta-1b |
| CN108727582A (en) * | 2017-04-21 | 2018-11-02 | 博瑞生物医药（苏州）股份有限公司 | Target anticancer conjugate |
| CN107137715A (en) * | 2017-04-26 | 2017-09-08 | 石家庄蒎格医药科技有限公司 | Prodrug and preparation is conjugated in a kind of 9-hydroxy-risperidone polyethylene glycol |
Non-Patent Citations (1)
| Title |
|---|
| 苟鹏飞: "新型阿霉素前药PEG-DOX的合成、表征及体内外研究", 《中国优秀硕士论文全文数据库医药卫生科技辑》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110124048B (en) | 2022-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102153536B (en) | Mangiferin aglycon derivative, as well as preparation method and application of the mangiferin aglycon derivative | |
| WO2005092898A1 (en) | The conjugates of a hydrophilic polymer-tripterygium's extracts and the pharmaceutical compositions thereof | |
| WO2003074586A1 (en) | Compound of hydrophilic polymer-polycarboxyl oligopeptide and medicines, medical composite comprising above compound and use of above compound in medicimes | |
| CA2623117C (en) | Novel crystal forms of irinotecan hydrochloride | |
| CN108570046A (en) | A kind of berberine-Chrysin pharmaceutical co-crystals and preparation method thereof | |
| CN112209988B (en) | Tea sapogenin thiosemicarbazone zinc complex and preparation method and application thereof | |
| CN107286220B (en) | 1,2, 4-triazole coupled dihydromyricetin derivative and preparation method and application thereof | |
| CN102796254A (en) | Pegylated celastrol and preparation method and application thereof | |
| CN104004037B (en) | 8-position methylamine like derivative of baicalin and ester thereof and preparation method thereof | |
| CN102603858B (en) | Azacycle-containing derivative of betulinol, preparation method thereof, and purpose thereof | |
| CN1947796B (en) | Chemical modified adefovir and tynofovir | |
| CN110124048A (en) | Multi-arm polyethylene glycol matrine conjugate, preparation method and application | |
| CN108864072B (en) | Coumarin thiadione compound and preparation method and application thereof | |
| CN109988104B (en) | Kaempferol and isonicotinamide eutectic crystal, preparation method, pharmaceutical composition and application thereof | |
| CN102766134A (en) | Dabigatran etexilate derivative and preparation method and application thereof | |
| CN110128482A (en) | A kind of preparation method and applications of novel Pt (IV) complex with cancer target | |
| CN113082222B (en) | Peptide-based nano-drug targeting tumor cell mitochondria and preparation method and application thereof | |
| CN101648948B (en) | Medicine of 3-alkoxyl-mangiferin for lowering blood pressure, synthesis and application | |
| CN110092789B (en) | Indolo [2,3-b ] carbazole derivative and application thereof | |
| CN110152013B (en) | Pectin-adriamycin conjugate and preparation method and application thereof | |
| CN110418653B (en) | Pectin-adriamycin conjugate and preparation method and application thereof | |
| CN113801181A (en) | Flavonoid glycoside-organic amine anti-tumor agent double-salt compound and preparation method and application thereof | |
| CN108164476B (en) | Isophthalonitrile compound, application thereof and medicine containing compound | |
| CN106478938B (en) | PEG modifier and its preparation of a kind of cucoline and its derivative | |
| CN104650342B (en) | Highly branched chain polymeric drug precursor and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |